LMR Partners’s ALX Oncology ALXO Stock Holding History

LMR Partners’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,000	Closed	-$151K	–	1264
2024 Q2	$151K	Buy	+25,000	New	+$307K	﹤0.01%	876

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's ALXO Position: Q3 2024 in Review

LMR Partners sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 25,000 shares — an estimated $151K sold.

LMR Partners first reported a position in ALXO in Q2 2024 and held it in 1 quarter. The position peaked at $151K in Q2 2024. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

LMR Partners reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
LMR Partners sold 25,000 ALX Oncology shares in Q3 2024, an estimated $151K.
LMR Partners first reported a position in ALX Oncology in Q2 2024 and held it in 1 quarter.
LMR Partners's ALX Oncology position peaked at $151K in Q2 2024.
92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.